Alkem Laboratories Limited is a leading pharmaceutical company based in Mumbai, India, specializing in the development, manufacture, and sale of pharmaceutical and nutraceutical products. Its primary offerings include branded generics, generic drugs, and active pharmaceutical ingredients (APIs).

The company reported a robust 17% revenue growth in Q2 FY26, with EBITDA margins improving to 23%. It has shown significant growth across India, the US, and international markets, largely driven by new product launches and strong performance in key therapeutic areas.

Alkem has become the number one company in the Acute segment within the Indian Pharmaceutical Market (IPM) for Q2 FY26 and outperformed industry growth in important therapy areas such as anti-infectives and gastrointestinal disorders.

The company's growth strategy is supported by a focus on innovation and a large pipeline of ANDA filings in the US, with 187 ANDAs submitted and 163 approved as of September 2025. This positions Alkem as a strong player in the U.S. generic market.

Investment in new business areas like biologics and the establishment of manufacturing facilities for biosimilars underline Alkem's strategic expansion efforts, enhancing its competitive edge in both domestic and international markets.